Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment

NCT06848894 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT06848894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06848894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment
Lead sponsor
Beijing Tiantan Hospital
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
April 21, 2025
Completion date
December 31, 2027
Enrollment
1,204 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke